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Background: Small changes of bilirubin and liver enzymes are often detected during the acute phase of stroke, but
their origin and significance are still poorly understood.
Methods: On days 0, 3, 7, and 14 after admission, 180 patients with ischemic stroke underwent serial determinations
of bilirubin, GOT, GPT, γGT, alkaline phosphatase, C-reactive protein (CRP) and complete blood count. On days 0 and 7
common bile duct diameter was measured by ultrasound, and on day 3 cerebral infarct volume (IV) was calculated
from CT scan slices.
Results: During the first week GOT, GPT, γGT (P < 0.001) and CRP (P = 0.03) increased with subsequent plateau,
while significant decrements (P < 0.001) concerned unconjugated bilirubin, erythrocytes and haemoglobin.
Alkaline phosphatase, direct bilirubin and common bile duct diameter remained stable. IV correlated with CRP,
leukocytes, GOT, γGT (r > 0.3, P < 0.001 for all) and direct bilirubin (r = 0.23, P = 0.008). In multivariate analysis only
CRP and GOT remained independently associated with IV (P < =0.001). The correlation of IV with GOT increased
progressively from admission to day 14. GOT independently correlated with GPT which, in turn, correlated with
γGT. γGT was also highly correlated with leukocytes. Unconjugated bilirubin correlated with haemoglobin, which
was inversely correlated with CRP.
Conclusions: The changes of bilirubin and liver enzymes during ischemic stroke reflect two phenomena, which
are both related to IV: 1) inflammation, with consequent increment of CRP, leukocytes and γGT, and decrease of
haemoglobin and unconjugated bilirubin and 2) an unknown signal, independent from inflammation, leading to
increasing GOT and GPT levels.
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Some previous studies have reported an increment of
bilirubin levels during ischemic or haemorrhagic stroke,
and their association with the severity of symptoms
[1,2]. These results (concerning in particular direct
bilirubin [1]), could be related to the anti-oxidant action
of this molecule, which might counteract the oxidative
processes contributing to cerebral damage during the
acute phase [3,4].* Correspondence: antonio.muscari@unibo.it
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unless otherwise stated.Changes during the acute phase of stroke have also been
reported for gamma-glutamyl-transferase (γ-GT) [5], an
enzyme that is typically associated with cholestasis and
alcohol consumption. In particular, γ-GT might increase
due to a contraction of the sphincter of Oddi caused by
alterations of the autonomic nervous system, or by a
fast-related reduction of cholecystokinin secretion [5].
But even a direct release of γ-GT and alkaline phosphatase
(ALP) from cerebral lesions cannot be ruled out, as
these enzymes are present in the endothelium of cerebral
capillaries and therefore they might behave as markers of
blood–brain barrier lesion [6]. In addition, γ-GT would
have a long term predictive significance for new cases ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 General characteristics of the study population
(N = 180)
Characteristic Value
Age (years) 73.2 ± 13.2
Male sex 85 (47.2)
Cerebral lesion volume (ml) 4.7 [0.4-35.5]
Admission to emergency dept. delay (hrs)* 1.7 [0.8-6.3]







Large artery 28 (15.6)
Cardioembolism 57 (31.5)
Small artery 45 (25.0)
Other cause 6 (3.3)
Undetermined 44 (24.4)
Initial NIHSS score 6 [3-15]
<10 112 (62.2)
> = 10 and < 18 36 (20.0)
> = 18 32 (17.8)
Diabetes 41 (22.8)
Hypertension 152 (84.4)
Current smoker 35 (19.4)
Ex-smoker 31 (17.2)
Hypercholesterolemia 112 (62.2)
Malignant neoplasm 12 (6.7)
Previous myocardial infarction 32 (17.8)
Previous stroke 29 (16.1)
Previous TIA 9 (5.0)
Statin (pre-admission) 46 (25.6)
Clopidogrel (pre-admission) 14 (7.8)
Oestro-progestinic (pre-admission) 2 (1.1)
Values are number (percentage), or mean ± SD, or median [25th-75th percentile].
*Delays are referred to stroke onset.
LACS= lacunar anterior circulation syndrome, NIHSS = National Institutes of Health
Stroke Scale, OCSP =Oxfordshire Community Stroke Project, PACS= partial anterior
circulation syndrome, POCS = posterior circulation syndrome, TACS = total anterior
circulation symdrome, TOAST = Trial of ORG 10172 in Acute Stroke Treatment.
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which in turn is a recognized risk factor for stroke [9,10].
In the Atorvastatin During Ischemic Stroke (ADIS)
study, a double-blind controlled randomized investiga-
tion, we assessed the short-medium term effects of the
administration of high-dose atorvastatin during the
first week of ischemic stroke [11]. In the two groups
of patients very significant (although not very wide)
increments of glutamate-oxaloacetate-transaminase (GOT),
glutamate-piruvate-transaminase (GPT) and γ-GT serum
levels were detected during the week of study. The
increment of transaminases, in particular, which had
previously been reported only sporadically and mainly
in the cerebrospinal fluid [12,13], occurred in most
patients of both groups.
Overall, these data suggest that, beyond the explana-
tions so far proposed to justify the increases in bilirubin
and γ-GT, there may be a true involvement of the liver
in stroke. The present prospective study was performed
to describe more precisely the changes of bilirubin and
liver enzymes in the acute phase of ischemic stroke,
and to search for their possible explanations, consider-
ing in particular the relationships with cerebral lesion




The study started on April 1, 2011, and the last patient
was enrolled on June 27, 2012. During that period the
patients with suspected stroke (sudden and persistent
focal neurological deficit) were admitted to the Emergency
Department of our Hospital, where they underwent
the first laboratory assessment and CT scan, and were
possibly treated with rT-PA. After a variable period of
time (depending on the type of treatment and the time
of admission, see Table 1) 313 patients with suspected
ischemic stroke were transferred to our Stroke Unit.
Subsequently, 133 of them were excluded due to the
following criteria: thrombolytic treatment (possible inter-
ference with serum turnover of enzymes and bilirubin,
29% of exclusions), diagnosis of TIA or other disease
different from ischemic stroke (25%), delay from onset
of symptoms > 72 hours (17%), refusal to provide the
informed consent (11%), HBsAg or anti-HCV positivity
(10%), alcohol abuse (>3 alcoholic units/day, 6%), or
other exclusion criteria (jaundice of any type, present
or previous inflammatory or neoplastic pathology of
the pancreas or biliary tree, 2%). Eventually the study
participants were 180 (mean age 73.2 ± 13.2 years, 53%
women, see Table 1). In the ADIS Study [11], in 31
patients with ischemic stroke a mean increment of 5 ± 8 U
of both GOT and γ-GT was obtained after 7 days from
admission (P = 0.001). Hypothesizing, for the presentstudy, a mean increment of only 3 ± 8 U with a P value
of 0.01, 110 patients would be needed to get a power of
90% (a size well below the number of our patients, even
considering missing data).
The severity of neurological deficit was assessed by the
National Institutes of Health Stroke Scale (NIHSS) on
admission, at discharge, and every time it was deemed
necessary according to clinical picture variations.
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or inability of understanding) signed the informed consent
form. The study was approved by the joint University-
Hospital Ethics Committee, and was conducted according
to the criteria of the Helsinki Declaration.
Study variables
On admission to Stroke Unit (median delay from stroke
onset 16.8 hours, see Table 1), and after 7 days, the patients
underwent a venous blood drawing for a complete blood
count and the determination of the following serum
parameters: GOT, GPT, ALP, γ-GT, total biliribin, direct
bilirubin (unconjugated bilirubin = total – direct blirubin)
and C-reactive protein (CRP). In addition, at the same
times 2 abdominal ultrasound assessments were per-
formed, for the measurement of common bile duct and
inferior vena cava diameter, and the search for possible
intrahepatic bile duct dilatation, liver steatosis and gall-
bladder stones.
Moreover, on days 3 and 14 the measurements of liver
markers (GOT, GPT, ALP, γ-GT and fractionated biliru-
bin) were repeated. Finally, the transaminases (GOT and
GPT) were also measured on admission to the Emergency
Department (median delay from stroke onset 1.7 hours,
see Table 1).
All laboratory determinations were performed in the
Central Laboratory of our Hospital, using automated
procedures and commercially available kits: AST and ALT
Cobas (UV test) for the measurement of transaminases,
ALP2 Cobas (colorimetric test) for the measurement of
ALP, GGT-2 Cobas (enzymatic colorimetric test) for the
measurement of γ-GT, TBILI and BILD2 Cobas (method
with diazoreagent) for the measurement of fractionated
bilirubin, and Tina-quant CRP-Latex for the measurement
of high sensitivity CRP. All kits were produced by Roche
Diagnostics, Mannhein, Germany. Finally, the complete
blood counts were performed by an automated counter
(Bayer ADVIA 120).
Generally on admission to Stroke Unit, or on the fol-
lowing day, a supra-aortic ultrasound assessment was
performed, while on day 3 a second brain CT scan (in
addition to the one performed in the Emergency Depart-
ment) was performed to precisely define the site and
volume of cerebral infarct.
For each patient the infarct volume, expressed in ml,
was obtained by one of the authors (A.C.) from the 3rd
day scan measuring the lesion area in each CT slice, then
adding up all the lesion areas, and multiplying the result
by the mean slice thickness.
Statistical analysis
The study variables are described by mean ± SD in case of
normal distribution, or median and interquartile interval
in case of non-gaussian distribution. The differencesbetween means were tested by Student’s t, while the differ-
ences between medians were assessed by Mann-Whitney’s
U test. The comparisons between 2 different times of
the same variable were assessed with Student’s t for
paired data or with Wilcoxon’s test, as appropriate. The
differences between percentages were tested by χ2. All
simple correlations were assessed by Pearson’s r coeffi-
cients after logarithmic transformation of the variables
with non-gaussian distribution. Multivariate analysis was
performed by multiple linear regressions and standardized
β coefficients, with backward elimination of the non-
significant associations. Also in this case the log-normal
variables were previously log-transformed. P values < 0.05
were considered significant and two-tail tests were used
throughout. The analyses were performed using SYSTAT
10 (SPSS Inc, Chicago, IL, USA).
Results
The general characteristics of the sample population are
illustrated in Table 1. Overall there was a prevalence
of hypertensive, hypercholesterolemic and with mild
symptoms patients. The median value of cerebral infarct
volume was 4.7 ml (range 0–462.3).
Variables changing during the acute phase of stroke
Table 2 reports the mean or median values of the study
variables, both on admission and on the 7th day. Missing
values increased with time, and concerned different
variables from one patient to another. Thus, the variables
had different sample sizes, considering also that for each
variable both values (on admission and on the 7th day)
had to be available.
Both on admission and on the 7th day the upper limit
of the interquartile interval of direct bilirubin, leukocytes
and CRP exceeded their maximum normal value: thus,
more than a quarter of the patients had high values of
these variables already on admission. GOT, GPT, γGT
and platelets displayed small (generally within the
normal range) but highly significant increments, while
CRP had a less significant increment. On the other hand,
unconjugated bilirubin, erythrocytes, haemoglobin and
leukocytes decreased significantly.
The mean or median values on the 3rd and 14th day
are not reported since none of them differed significantly
from the mean or median values obtained, respectively,
on admission and on the 7th day. Thus, during the second
week all variables displayed a “plateau” course. Moreover,
due to the random presence of missing values, the
addition of these data to the Table would have caused a
further reduction in sample size.
Since ALP and direct bilirubin did not change, they will
not be further considered in the following analysis. Table 3
shows the simple correlations between the logarithm of
the infarct volume and the values on admission, the values
Table 2 Time course of liver enzymes, bilirubin, blood counts and C-reactive protein
Variable Normal range N Admission 7th day P
GOT (U/l) <38 138 19 [14-24] 22 [16–30] <0.001
GPT (U/l) <41 140 15 [11-21] 20 [13–33.5] <0.001
γGT (U/l) <61 138 22 [15–32] 26 [19–42] <0.001
ALP (U/l) <130 133 76 [59–108] 75 [62–106] 0.48
Unconjugated bilirubin (mg/dl) <0.80 119 0.43 [0.31-0.64] 0.33 [0.23-0.43] <0.001
Direct bilirubin (mg/dl) <0.30 119 0.26 [0.19-0.37] 0.25 [0.18-0.33] 0.13
Erythrocytes (n/106/mmc) 4.50-6.10 141 4.89 ± 0.67 4.72 ± 0.65 <0.001
Haemoglobin (g/dl) 13.0-16.5 142 13.6 ± 1.9 13.1 ± 2.2 <0.001
WBC (n/103/mmc) 4.20-9.00 136 8.71 [6.95-10.41] 7.76 [6.42-9.88] 0.002
Platelets (n/103/mmc) 150-380 138 224.8 ± 77.8 240.7 ± 90.6 <0.001
CRP (mg/dl) <0.80 118 0.80 [0.27-3.58] 1.67 [0.36-4.38] 0.03
Values for admission and 7th day are medians [25th-75th percentile] or means ± SD.
ALP = Alkaline phosphatase, CRP = C-reactive protein, GOT = Glutamate oxaloacetate transaminase, GPT = glutamate piruvate transaminase, γGT = gamma glutamyl
transferase, WBC =white blood cells.
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and admission, of the 9 variables that varied during the
acute phase of stroke. GOT, γGT, leukocytes and CRP
were directly correlated with the volume of the ischemic
lesion, particularly on the 7th day. Thus, the 7th day
values of the 9 variables listed in Table 3 were included in
a multivariate model (multiple linear regression), with the
logarithm of cerebral infarct volume as dependent variable
(Table 4, N = 110). The model was also adjusted for age,
sex and initial NIHSS score. After backward elimination
of the non-significant associations, only log(CRP) and
log (GOT) remained independently associated with the
logarithm of infarct volume (overall R2 = 0.28, P < 0.001).
Seventy patients were not included in this analysis as they
were lacking of some of the above 9 variables. Thus, we
compared the general characteristics (see Table 1) of these
70 patients with those of the 110 patents that had all the
data. There were no significant differences for most of the
variables considered, including, in particular, age, infarctTable 3 Simple correlations of the study variables with the lo
Variable Admission
N r P N
Log (GOT) 172 0.24 0.002 13
Log (GPT) 173 0.14 0.08 13
Log (γGT) 173 0.11 0.15 13
Log (Unconjugated bilirubin) 160 0.04 0.63 12
Erythrocytes 171 −0.03 0.48 14
Haemoglobin 172 −0.04 0.59 14
Log (WBC) 170 0.38 <0.001 13
Platelets 172 0.08 0.28 13
Log (CRP) 163 0.33 <0.001 12
Only the variables with significant changes during the first week are shown.
CRP = C-reactive protein, GOT = Glutamate oxaloacetate transaminase, GPT = glutam
blood cells.volume and NIHSS score. The two groups differed only
for sex (57.1% males among the patients with missing
data, vs. 40.9% among the other patients, P = 0.03), and
for the prevalence of previous TIA (respectively, 0 vs.
8.2%, P = 0.01).
The 9 variables that changed during the acute phase
were variously correlated to each other. Table 5 shows,
and Figure 1 graphically outlines, the independent corre-
lations of each of these variables with the other variables
(multiple linear regressions with backward elimination
of non-significant associations). The figure also reports
the independent associations with cerebral infarct volume.
All the variations of the variables considered in this study
seem to be attributable to 2 main changes, namely those
concerning GOT and CRP, which in turn were the only
variables independently associated with cerebral infarct
size. Inflammation is responsible for the increase in
CRP, leukocytes and platelets, and also contributes to
the increase in γGT. In addition, CRP is inverselygarithm of cerebral infarct volume
7th day Δ (7th day - Admission)
r P N r P
7 0.35 <0.001 136 0.07 0.42
8 0.16 0.07 138 −0.00 0.96
6 0.34 <0.001 136 0.29 <0.001
9 0.04 0.63 117 −0.07 0.43
1 −0.02 0.82 139 −0.03 0.68
1 −0.01 0.94 140 0.04 0.64
6 0.36 <0.001 134 0.08 0.37
7 0.07 0.42 136 0.02 0.83
3 0.41 <0.001 116 0.29 0.002











Figure 1 Schematic representation of the independent
associations with infarct volume reported in Table 4 and of the
independent associations among the study variables reported
in Table 5. The strongest associations (standardized β > =0.3,
P < 0.001) are shown in bold. Minus signs indicate inverse associations.
CRP = C-reactive protein, GOT = Glutamate oxaloacetate transaminase,
GPT = glutamate piruvate transaminase, γGT = gamma glutamyl
transferase, RBC = red blood cells, WBC = white blood cells.
Table 4 Significant multivariate associations between the
study variables (7th day determination) and the logarithm
of cerebral infarct volume
Variable β S.E. Standardized β P
Log (GOT) 1.367 0.557 0.200 0.01
Log (CRP) 0.565 0.171 0.310 0.001
Age −0.011 0.022 −0.048 0.61
Male sex −0.520 0.500 −0.085 0.30
Log (Initial NIHSS score) 0.518 0.188 0.240 0.007
Intercept −3.090 2.466 - 0.213
Result of a multiple linear regression (N = 110) with the logarithm of cerebral
infarct volume as dependent variable and all variables listed in Table 3 as
initial independent variables, after backward elimination of non-significant
associations. The model includes also age, sex and initial NIHSS score as
adjustment factors.
CRP = C-reactive protein, GOT = Glutamate oxaloacetate transaminase,
NIHSS = National Institutes of Health Stroke Scale.
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together with red blood cells and unconjugated bilirubin
(see also Table 2).
GOT levels are independently influenced by cerebral
infarct volume, but are also associated with CRP levels
(β = 0.18). It is therefore possible that the effect of a variable
on GOT levels may vary in relation to the variations of the
other variable. To test this hypothesis we constructed a
linear regression model including log(GOT) as dependent
variable, and log (infarct volume), log(CRP) and log(infarct
volume) X log(CRP) (interaction term) as independent
variables. In this analysis only log(infarct volume) remained
associated with log(GOT) (β = 0.26, P = 0.007), while both
log(CRP) (β = −0.011, P = 0.92) and the interaction term
(β = 0.112, P = 0.25) were not significant, so that the
hypothesis of an interaction between the 2 variables
(infarct volume and CRP) on GOT levels was rejected.
Thus, the association between GOT and infarct volume
seems to be independent from inflammation, and appearsTable 5 Significant multivariate associations among the study
Dependent variable In
Log (GOT) Log (GPT) Log (γGT) Log (Unc.Bil
Log (GOT) 0.78c





Log (WBC)) −0.19a 0.34c
Platelets
Log (CRP)
Results of multiple linear regressions (standardized β coefficients), with backward e
aP < 0.05, bP < 0.005, cP < 0.001.
CRP = C-reactive protein, GOT = Glutamate oxaloacetate transaminase, GPT = glutam
blood cells.of particular interest. The correlation between the loga-
rithm of infarct volume and the logarithm of GOT was
not present on admission to the Emergency Department
(median delay from onset of symptoms 1.7 hours; r = 0.13;
P = 0.11; N = 158), it was first detectable on admission to
Stroke Unit (median delay 16.8 hours; r = 0.24; P = 0.002;
N = 172), it increased on the 7th day (r = 0.35; P < 0.001;
N = 137), and was maximum on the 14th day (r = 0.50;
P < 0.001; N = 95).
Direct bilirubin
As above reported, direct bilirubin did not change signifi-
cantly between admission and 7th day. However, on the 7th
day a significant correlation (N = 129, r = 0.23, P = 0.008)
was observed between the logarithm of direct bilirubin and
the logarithm of infarct volume, which was not present on
admission. But when the logarithm of direct bilirubin wasvariables (7th day determination, N = 112)
dependent variables







0.31c 0.30c 0.52c 0.61c
−0.23a 0.38c 0.18c
−0.34c 0.65c 0.50c
limination of non-significant associations.
ate piruvate transaminase, γGT = gamma glutamyl transferase, WBC = white
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ated with the logarithm of infarct volume, this variable was
immediately eliminated, showing that its association with
infarct volume was not independent.
The multivariate search for the factors associated with
direct bilirubin showed its independent associations with
the logarithm of unconjugated bilirubin (P < 0.001), the
logarithm of γGT (P = 0.001) and the logarithm of com-
mon bile duct diameter (P = 0.03).
Ultrasound parameters
None of the ultrasound variables considered in this
study (common bile duct diameter, inferior vena cava
diameter and intrahepatic bile duct dilatation) changed
significantly between admission and 7th day. With the
exception of the above reported correlation between
the logarithm of common bile duct diameter and the
logarithm of direct bilirubin, no correlations were found
among ultrasound parameters and the laboratory variables
assessed in this study. Among the patients with available
measurements of common bile duct diameter, plus γ-GT
and GOT on the 7th day (N = 94), the high quintile of
common bile duct diameter (0.6-1.0 cm) consisted of 17
patients, who included 8 of the 9 patients previously
subjected to cholecystectomy. The cholecystectomized
patients were then excluded, and 9 patients remained with
an apparently unexplained common bile duct dilatation.
The Glasgow Coma Score of these patients was signifi-
cantly lower than that of the rest of the sample: 10 [9-15]
vs. 15 [13-15], P = 0.04, but the 2 groups did not differ in
the median values of γ-GT and GOT.
Discussion
This study has shown that the small but significant changes
of liver enzymes and bilirubin occurring during the early
phase of ischemic stroke are attributable, directly or indir-
ectly, to the size of cerebral infarct. To a large extent such
changes are due to inflammation, but this is not the case
for serum GOT, which is influenced by infarct size with
mechanisms that are presently unknown.
Inflammation, unconjugated bilirubin and γGT
The strong independent correlation of ischemic lesion
volume with CRP demonstrates that inflammation during
stroke course is directly proportional to cerebral damage,
as already reported by Ormstad et al. [14].
Inflammation is a recognized important cause of anemia
[15], deriving from at least three different mechanisms
mediated by inflammatory cytokines: inhibited production
of erythropoietin, reduced response of the erythroid pro-
genitors to erythropoietin, and reduced iron release from
stores caused by the polypeptide hormone hepcidin
[16,17]. Also in this study, as in others previously [18],
a strong inverse correlation was shown between CRPand haemoglobin. Thus, in the acute phase of stroke, in
addition to the increase in CRP, white blood cells and
platelets, a decrease in haemoglobin and red blood cells
occurs (the small decrement of white blood cells during
the first week probably follows a rapid initial increment,
as suggested by the high median value of white blood
cells on admission to Stroke Unit). Unconjugated bilirubin
is a heme by-product, so it is directly proportional to
haemoglobin. Therefore, the significant fall of uncon-
jugated bilirubin in acute stroke seems to be a simple
epiphenomenon of haemoglobin fall.
Finally, we found a strong independent association be-
tween white blood cells and γGT, so that also the increase
of this enzyme in acute stroke is probably influenced
by inflammation, as suggested by a few data reporting
a connection between inflammation and γGT [19,20].
In previous studies γGT was found to be predictive of
cardiovascular risk [21,22] and, in particular, of the risk of
stroke [8] even independently of alcohol consumption [23].
Thus, the association between γGT and cardiovascular risk
may be due, to a large extent, to the fact that inflammation
is an important cardiovascular risk factor [24].
γGT is also a marker of cholestasis, and previously
Sevastos et al. detected a common bile duct dilatation in
a minority (4.1%) of stroke patients [5]. All such patients
were in a deep coma, so that the authors hypothesized an
inordinate hypertonia of the sphincter of Oddi induced
by a severe autonomic and hypothalamic impairment. In
fact our analysis confirmed that the stroke patients with a
dilatation of the common bile duct that was not due to pre-
vious cholecystectomy presented a significantly more severe
degree of coma than the rest of the sample. However, this
aspect concerned only few patients, and could not explain
the progressive increment of liver enzymes in the whole
sample. In particular, no change in common bile duct
diameter was found during the first 7 days in Stroke Unit,
and other markers of cholestasis, such as direct bilirubin
and ALP, did not show any variation.
GOT and liver involvement
In this study GOT was the only enzyme directly and
independently correlated with cerebral infarct size. This
fact is in sharp contrast with the results obtained by
Campos et al. [25], who found instead an inverse relation-
ship between serum levels of GOT and infarct volume in
patients with ischemic stroke. These authors proposed the
hypothesis that GOT may exert a protective role, as it is
capable of metabolizing, and therefore neutralizing, the
toxic glutamate [26,27] that is released from the ischemic
cerebral tissue into the blood. Thus, infarct size would be
influenced by the pre-existing levels of GOT, and would
be greater in the patients with a poor production of pro-
tective GOT. Our data demonstrate instead that there is a
progressive increment in GOT levels, with a maximum
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eau, and that the correlation with infarct volume is not
only direct, but also increasingly stronger with the passing
of time after the acute event. Thus, our results show that
GOT production is influenced by cerebral infarct volume,
and not vice versa. It seems probable that some substance
released from cerebral infarct and different from inflam-
matory cytokines (perhaps glutamate itself ), is capable
of stimulating the production of GOT (whose possible
protective effect is however not excluded).
The differences with the study by Campos et al. [25]
may have several explanations. Firstly, these authors
measured GOT levels only on admission, i.e. on average
in their study nearly 3 hours after stroke onset, while in
the present study the strongest relationships between
GOT and infarct volume were found on the 7th and
14th day. However, in our patients even when GOT was
measured on admission to the Stroke Unit a significant
direct relationship with infarct volume was found, while
when GOT was measured in the Emergency Department
(median delay from onset of symptoms 1.6 hours) no
correlation with infarct volume was found, and in any
case the relationship was not of inverse type. Furthermore,
the sample by Campos et al. was rather different from
ours, as 35% of their patients had been thrombolysed
(while thrombolysed patients had been excluded from our
sample), cardioembolic strokes were over-represented
(50%), and lacunar strokes were under-represented (4%).
Finally, in our study the infarct volume was measured
in a more precise way, and log-transformed values were
used in the calculation of linear regressions between
non-gaussian variables.
Although GOT increments during stroke have been
reported also in cerebrospinal fluid [12,13], the chained
correlations among this enzyme, GPT and γGT suggest
that its synthesis probably occurs in the liver. Also a direct
release of GOT from necrotic cerebral tissue does not
seem probable, as the appearance of the enzyme in blood
does not follow a log-normal course (with early peak and
subsequent progressive decrease), as is the case, for ex-
ample, after a myocardial infarction. Instead the enzyme
gradually accumulates in blood, with a progressive increase,
and a plateau persisting at least until the 14th day.
Further studies are needed to clarify the mechanisms
underlying the apparently independent association between
cerebral lesion size and serum GOT levels. At present, the
hypothesis that the release of toxic glutamate by the ische-
mic cerebral tissue [26,27] may induce the hepatic synthesis
of the main enzymes involved in the metabolism of this
neurotransmitter remains the most probable one.
Direct bilirubin
Direct bilirubin displayed no variations during the acute
phase of stroke. However, in some cases its levelsexceeded the maximum normal value on both admission
and 7th day. Furthermore, the values measured on the
7th day correlated with infarct volume, and previously
direct bilirubin was found to be associated with stroke
severity as assessed by the NIH stroke scale [1,28]. In
our study multivariate analysis showed that the main
determinants of direct bilirubin were unconjugated
bilirubin and γGT: the former is evidently the substrate
from which direct bilirubin originates, while the latter,
during the course of stroke, is probably synthesized by
the liver in response to factors including inflammation
(see above), which in part might also trigger the glucur-
onoconjugation of bilirubin. Since during the first week
after stroke onset unconjugated bilirubin decreases
and γGT increases, the net result on the trend of direct
bilirubin could be a plateau. Furthermore, the association
of direct bilirubin with γGT may explain the asso-
ciation with infarct volume, and consequently with
stroke severity.Limitations
The patients were admitted to our Stroke Unit after
having spent a variable period of time in the Emergency
Department. It is possible that during this early phase
some markers (especially CRP, leukocytes and direct bili-
rubin) may have had a sharp rise that was not detected.
The measurement of serum glutamate might have
allowed a better understanding of the pathophysiologic
mechanisms involved.Conclusions
This study suggests that the liver participates to a variable
extent in the acute phase of ischemic stroke, producing
enzymes in response to signals coming from cerebral
infarct and proportional to its size. An important signal
is likely represented by inflammatory cytokines, which
induce the production of acute phase reactants such as
CRP and probably γGT. Another signal, presently unknown
and perhaps coinciding with toxic glutamate, triggers
the synthesis of GOT and indirectly of GPT. Instead,
unconjugated bilirubin progressively decreases, together
with haemoglobin, in response to inflammation, while
direct bilirubin does not show any significant variation.
Also, the hypothesis that the changes of liver enzymes
and bilirubin are related to extrahepatic cholestasis was
not confirmed: this phenomenon probably concerns
only a small minority of comatose patients.
In conclusion, GOT is the only liver enzyme directly
associated with the ischemic cerebral lesion independently
from inflammation. Possibly this enzyme, neutralizing
the toxic glutamate, might play a protective role, as some
reports on its favourable prognostic significance suggest
[25,29].
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